CD34 and Miyoshi myopathy: Considering that the CD34+ stem cells of 2 × 106/kg or greater and of 5 × 106/kg or greater, respectively, are required to avoid delayed or failed engraftment and to achieve more rapid platelet recovery [8,9,10], it is possible to choose a reasonable count between CD34+ stem cells of 4 × 106/kg to 10 × 106/kg or greater to be determined in MM patients with the possibility of receiving a second course of ASCT, as in previous reports and guidelines [14,23,25].